case_images: PMC10598860_01
case_images: Thorax CT imaging of the patient before and after treatment of tislelizumab plus albumin-bound paclitaxel. (A-D) show the CT imaging at baseline, the end of the second cycle, the third cycle, and the fifth cycle, respectively. (A) Baseline imaging on 19 May 2020; (B) imaging on 16 July 2020, after two cycles treatment; (C) imaging on 9 September 2020, after three cycles treatment; (D) imaging on 3 November 2020, after five cycles treatment.
case_images: fonc-13-1242460-g001.jpg
case_images: PMC10598860_01_fonc-13-1242460-g001.jpg
case_images: f1
case_images: Thorax CT imaging showed irregular masses involving the ascending aorta, the aortic arch, the superior vena cava, the pulmonary artery, and the trachea and main bronchi; multiple enlarged lymph nodes in the mediastinum; and diffuse irregular thickening of the pericardium ( Figure 1A ). The patient was assessed as having stable disease (SD) at the end of the second cycle treatment ( Figures 1B-D ). The change in cytokeratin is summarized in  Supplementary Figure 1 .
case_images: Thorax CT imaging indicates pulmonary inflammation after treatment of tislelizumab plus albumin-bound paclitaxel, which disappears in approximately 2 months when monitored closely. (A) Imaging on 16 July 2020, after two cycles immunotherapy, inflammation focally affecting the left lung; (B) imaging on 22 July 2020, 1 week after the time of (A), the inflammation is still in the left lung; (C) imaging on 9 September 2020, after three cycles immunotherapy, the inflammation basically subsided.
case_images: fonc-13-1242460-g002.jpg
case_images: PMC10598860_01_fonc-13-1242460-g002.jpg
case_images: f2
case_images: However, the patient was indicated with pulmonary fibrosis, which might be grade 1 checkpoint inhibitor pneumonitis (CIP) ( Figures 2A, B ), grade 2 leukopenia, and grade 3 thrombocytopenia. The CIP was closely monitored and got better when assessed on 22 July 2020 (Figures 2B, C).
case_images: The tumor progression by thorax and abdomen CT imaging. (A) Thorax imaging indicates enlarged lesions in the mediastinum on 16 March 2021; (B) abdomen imaging on 16 March 2021 indicates multiple live metastases.
case_images: fonc-13-1242460-g003.jpg
case_images: PMC10598860_01_fonc-13-1242460-g003.jpg
case_images: f3
case_images: CT imaging demonstrated enlarged lesions in the mediastinum and multiple live metastases ( Figures 3A, B ).
case_images: Summary of treatment timeline.
case_images: fonc-13-1242460-g004.jpg
case_images: PMC10598860_01_fonc-13-1242460-g004.jpg
case_images: f4
case_images: The treatment timeline is summarized in  Figure 4 .